May 2, 2024
amsterdam, netherlands – Argenx (Euronext & Nasdaq: ARGX), a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, today announced a conference call and audio on Thursday, May 9, 2024 at 2:30 p.m. They announced that they would be holding a webcast. At 8:30pm CET, we will discuss our first quarter 2024 financial results and provide a business update.
A webcast of the live call can be accessed from the Investors section of the argenx website (argenx.com/investors). A replay of the webcast will be available on his website at argenx for approximately one year after the presentation.
Dial-in number:
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 800 715 9871
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
Please use access code 1231519 to join the call. Please dial in 15 minutes before the live call.
About Argenx
argenx is a global immunology company dedicated to improving the lives of people living with severe autoimmune diseases. Through its Immunology Innovation Program (IIP), argenx aims to partner with leading academic researchers to translate breakthrough advances in immunology into a world-class portfolio of novel antibody-based medicines. argenx develops and commercializes the first neonatal Fc receptor (FcRn) blocker approved in the United States, Japan, Israel, the European Union, United Kingdom, Canada, and China. The company is evaluating efgartigimod in multiple serious autoimmune diseases and is advancing several early-stage experimental drugs within its therapeutic franchise. For more information, please visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook and YouTube.
For more information, please contact us below.
media:
ben petok
BPetok@argenx.com
Investor:
Alexandra Roy (USA)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com